(RTTNews) - Harrow Inc. (HROW), an eyecare pharmaceutical company, Thursday said ImprimisRx, a unit of Harrow, has won the trademark infringement case against OSRX, Inc. and its related party Ocular Science, Inc.
ImprimisRx had alleged trademark infringement against OSRX and Ocular Science.
The $34.9 million verdict by the United States District Court for the Southern District of California includes $20.4 million in punitive damages and $14.5 million in actual damages.
The court observed that OSRX, or Ocular Science willfully engaged in trademark infringement.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
